scenichu
2021-11-30
[Smile]
Novartis chairman says all options open for Sandoz unit - report
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609659746,"tweetId":"609659746","gmtCreate":1638281928096,"gmtModify":1638281928608,"author":{"id":3554951292305587,"idStr":"3554951292305587","authorId":3554951292305587,"authorIdStr":"3554951292305587","name":"scenichu","avatar":"https://static.tigerbbs.com/e2d5eb7de52de2d76f08c9564d26fe90","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":68,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Smile] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Smile] </span><br></p></body></html>","text":"[Smile]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609659746","repostId":2187679587,"repostType":4,"repost":{"id":"2187679587","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638278292,"share":"https://www.laohu8.com/m/news/2187679587?lang=&edition=full","pubTime":"2021-11-30 21:18","market":"us","language":"en","title":"Novartis chairman says all options open for Sandoz unit - report","url":"https://stock-news.laohu8.com/highlight/detail?id=2187679587","media":"Reuters","summary":"ZURICH, Nov 30 (Reuters) - Novartis is keeping all options open for the future of its generics divis","content":"<p>ZURICH, Nov 30 (Reuters) - Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday.</p>\n<p>Asked whether Novartis could merge Sandoz with either Israel's Teva or U.S.-based Viatris or divest it, Joerg Reinhardt said: \"All options are open for us.\" He said listing Sandoz on the Swiss stock exchange, a merger or keeping the business were all possible.</p>\n<p>\"We said we'd look at that and make a decision within the next 12 months,\" he said.</p>\n<p>Reinhardt said Novartis's innovative pharma business and the generics business had drifted further apart over the last years so it made sense to examine options now.</p>\n<p>Novartis said last month it might divest Sandoz, as price pressures mount in the off-patent drug sector.</p>\n<p>Asked how Novartis could use the proceeds from the sale of its Roche stake, Reinhardt said: \"We prefer investing in our business rather than doing a share buyback. We'll decide that within the coming months.\"</p>\n<p>Reinhardt didn't rule out acquisitions, saying it was important to see whether a possible target would strengthen Novartis's core business of oncology, cardiovascular and immunology.</p>\n<p>\"We'll examine, review and decide,\" he said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis chairman says all options open for Sandoz unit - report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis chairman says all options open for Sandoz unit - report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-30 21:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZURICH, Nov 30 (Reuters) - Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday.</p>\n<p>Asked whether Novartis could merge Sandoz with either Israel's Teva or U.S.-based Viatris or divest it, Joerg Reinhardt said: \"All options are open for us.\" He said listing Sandoz on the Swiss stock exchange, a merger or keeping the business were all possible.</p>\n<p>\"We said we'd look at that and make a decision within the next 12 months,\" he said.</p>\n<p>Reinhardt said Novartis's innovative pharma business and the generics business had drifted further apart over the last years so it made sense to examine options now.</p>\n<p>Novartis said last month it might divest Sandoz, as price pressures mount in the off-patent drug sector.</p>\n<p>Asked how Novartis could use the proceeds from the sale of its Roche stake, Reinhardt said: \"We prefer investing in our business rather than doing a share buyback. We'll decide that within the coming months.\"</p>\n<p>Reinhardt didn't rule out acquisitions, saying it was important to see whether a possible target would strengthen Novartis's core business of oncology, cardiovascular and immunology.</p>\n<p>\"We'll examine, review and decide,\" he said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","VTRS":"Viatris Inc.","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2187679587","content_text":"ZURICH, Nov 30 (Reuters) - Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday.\nAsked whether Novartis could merge Sandoz with either Israel's Teva or U.S.-based Viatris or divest it, Joerg Reinhardt said: \"All options are open for us.\" He said listing Sandoz on the Swiss stock exchange, a merger or keeping the business were all possible.\n\"We said we'd look at that and make a decision within the next 12 months,\" he said.\nReinhardt said Novartis's innovative pharma business and the generics business had drifted further apart over the last years so it made sense to examine options now.\nNovartis said last month it might divest Sandoz, as price pressures mount in the off-patent drug sector.\nAsked how Novartis could use the proceeds from the sale of its Roche stake, Reinhardt said: \"We prefer investing in our business rather than doing a share buyback. We'll decide that within the coming months.\"\nReinhardt didn't rule out acquisitions, saying it was important to see whether a possible target would strengthen Novartis's core business of oncology, cardiovascular and immunology.\n\"We'll examine, review and decide,\" he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1088,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609659746"}
精彩评论